Loading...

Anavex Life Sciences

DB:12X1
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
12X1
DB
$137M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The last earnings update was 72 days ago. More info.


Add to Portfolio Compare Print
  • Anavex Life Sciences has significant price volatility in the past 3 months.
12X1 Share Price and Events
7 Day Returns
-1.9%
DB:12X1
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
37.5%
DB:12X1
-10.2%
DE Biotechs
-6%
DE Market
12X1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Anavex Life Sciences (12X1) -1.9% -5.3% 60.8% 37.5% -42.6% -
DE Biotechs -2.4% 1.8% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.2% 7.4% -6% 10.1% 15.4%
1 Year Return vs Industry and Market
  • 12X1 outperformed the Biotechs industry which returned -10.2% over the past year.
  • 12X1 outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
12X1
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Anavex Life Sciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Anavex Life Sciences. This is due to cash flow or dividend data being unavailable. The share price is €2.5575.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Anavex Life Sciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Anavex Life Sciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:12X1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.46
NasdaqCM:AVXL Share Price ** NasdaqCM (2019-04-18) in USD $2.89
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Anavex Life Sciences.

DB:12X1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:AVXL Share Price ÷ EPS (both in USD)

= 2.89 ÷ -0.46

-6.31x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Anavex Life Sciences is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Anavex Life Sciences is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Anavex Life Sciences's expected growth come at a high price?
Raw Data
DB:12X1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.31x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Anavex Life Sciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Anavex Life Sciences's assets?
Raw Data
DB:12X1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.37
NasdaqCM:AVXL Share Price * NasdaqCM (2019-04-18) in USD $2.89
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.84x
DB:12X1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:AVXL Share Price ÷ Book Value per Share (both in USD)

= 2.89 ÷ 0.37

7.87x

* Primary Listing of Anavex Life Sciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Anavex Life Sciences is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Anavex Life Sciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Anavex Life Sciences has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Anavex Life Sciences expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Anavex Life Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.5%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Anavex Life Sciences expected to grow at an attractive rate?
  • Unable to compare Anavex Life Sciences's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Anavex Life Sciences's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Anavex Life Sciences's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:12X1 Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:12X1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:12X1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2019-09-30 0 -29 1
DB:12X1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -13 -21
2018-09-30 -13 -17
2018-06-30 -11 -17
2018-03-31 -12 -18
2017-12-31 -9 -14
2017-09-30 -9 -13
2017-06-30 -9 -15
2017-03-31 -8 -13
2016-12-31 -9 -14
2016-09-30 -9 -15
2016-06-30 -9 -14
2016-03-31 -8 -16

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Anavex Life Sciences is high growth as no earnings estimate data is available.
  • Unable to determine if Anavex Life Sciences is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:12X1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Anavex Life Sciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:12X1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2019-09-30 -0.58 -0.58 -0.58 1.00
DB:12X1 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.46
2018-09-30 -0.39
2018-06-30 -0.38
2018-03-31 -0.41
2017-12-31 -0.34
2017-09-30 -0.33
2017-06-30 -0.38
2017-03-31 -0.36
2016-12-31 -0.38
2016-09-30 -0.42
2016-06-30 -0.41
2016-03-31 -0.54

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Anavex Life Sciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Anavex Life Sciences's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Anavex Life Sciences's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Anavex Life Sciences's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Anavex Life Sciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Anavex Life Sciences has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Anavex Life Sciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Anavex Life Sciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Anavex Life Sciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Anavex Life Sciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Anavex Life Sciences's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Anavex Life Sciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Anavex Life Sciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:12X1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -20.73 6.35 13.73
2018-09-30 -17.45 5.99 11.71
2018-06-30 -16.81 5.87 11.14
2018-03-31 -17.58 5.65 12.08
2017-12-31 -14.37 5.28 9.30
2017-09-30 -13.46 5.01 8.65
2017-06-30 -14.82 6.86 8.18
2017-03-31 -13.45 6.59 7.04
2016-12-31 -13.93 6.09 7.56
2016-09-30 -14.74 8.33 6.68
2016-06-30 -13.58 8.34 4.06
2016-03-31 -15.58 7.92 3.70
2015-12-31 -15.28 7.75 3.12
2015-09-30 -12.11 4.84 2.27
2015-06-30 -15.05 1.91 1.87
2015-03-31 -11.82 1.93 1.33
2014-12-31 -11.11 2.38 1.05
2014-09-30 -9.97 2.24 0.73
2014-06-30 -4.66 3.31 0.49
2014-03-31 -3.80 2.67 0.26
2013-12-31 -2.89 1.92 0.27
2013-09-30 -3.70 1.87 0.26
2013-06-30 -1.39 0.95 0.28
2013-03-31 -5.78 1.15 0.63
2012-12-31 -6.58 1.34 0.94
2012-09-30 -8.30 1.52 2.65
2012-06-30 -9.05 1.69 3.13

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Anavex Life Sciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Anavex Life Sciences has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Anavex Life Sciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Anavex Life Sciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Anavex Life Sciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Anavex Life Sciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Anavex Life Sciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Anavex Life Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Anavex Life Sciences has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Anavex Life Sciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Anavex Life Sciences has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Anavex Life Sciences Company Filings, last reported 3 months ago.

DB:12X1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 17.22 0.00 20.76
2018-09-30 20.49 0.00 22.93
2018-06-30 23.59 0.00 25.83
2018-03-31 22.48 0.00 25.66
2017-12-31 25.55 0.00 28.05
2017-09-30 24.25 0.00 27.44
2017-06-30 23.45 0.00 24.79
2017-03-31 21.49 0.00 23.35
2016-12-31 19.18 0.00 21.16
2016-09-30 6.31 0.00 9.19
2016-06-30 7.67 0.09 9.73
2016-03-31 9.68 0.09 11.95
2015-12-31 11.49 0.08 13.85
2015-09-30 12.81 0.09 15.29
2015-06-30 6.57 0.15 7.96
2015-03-31 4.70 0.22 6.31
2014-12-31 0.47 0.32 6.98
2014-09-30 0.19 0.46 7.26
2014-06-30 7.41 0.20 8.18
2014-03-31 8.41 0.19 9.19
2013-12-31 -1.67 0.20 0.10
2013-09-30 -2.46 0.21 0.35
2013-06-30 -3.55 0.76 0.00
2013-03-31 -3.43 0.76 0.00
2012-12-31 -3.33 0.60 0.08
2012-09-30 -2.88 0.30 0.01
2012-06-30 -2.20 0.05 0.02
  • Anavex Life Sciences has no debt.
  • Anavex Life Sciences currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Anavex Life Sciences has sufficient cash runway for 1.6 years based on current free cash flow.
  • Anavex Life Sciences has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 17.7% each year.
X
Financial health checks
We assess Anavex Life Sciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Anavex Life Sciences has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Anavex Life Sciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Anavex Life Sciences dividends.
If you bought €2,000 of Anavex Life Sciences shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Anavex Life Sciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Anavex Life Sciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:12X1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:12X1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2019-09-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Anavex Life Sciences has not reported any payouts.
  • Unable to verify if Anavex Life Sciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Anavex Life Sciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Anavex Life Sciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Anavex Life Sciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Anavex Life Sciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Anavex Life Sciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Anavex Life Sciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chris Missling
COMPENSATION $2,538,889
AGE 52
TENURE AS CEO 5.8 years
CEO Bio

Dr. Christopher U. Missling, also known as the Chris, MS, Ph.D., MBA. has been the Chief Executive Officer and President at Anavex Life Sciences Corp. since July 05, 2013 and served as its Chief Financial Officer, Secretary and Treasurer since July 05, 2013. Dr. Missling serves as the Chief Financial Officer of SEE ALGAE Technology GmbH. He serves as a Secretary of Anavex Life Sciences Corp. Dr. Missling is a Partner of New York based investment bank Brimberg & Co and has over 15 years of finance experience. He is an Investment Banker at Deutsche Bank, serving companies across various industries. Dr. Missling served as Senior Vice President of Finance, Treasurer and Secretary of Asahi Kasei Pharma America Corporation (Previously known as Artisan Pharma, Inc.) Dr. Missling has extensive financial management, operational and strategic experience in the biotechnology and pharmaceutical industries. Dr. Missling served as the Chief Financial Officer of ImmunoGen Inc., from October 25, 2004 to January 2005 and also served as its Vice President of Finance and Treasurer. He also served as the Chief Financial Officer, Senior Vice President of Finance, Treasurer and Secretary of Curis, Inc. from August 2002 to November 2003 and Senior Vice President of Strategic Analysis and Planning from November 2003. Dr. Missling served as Chief Financial Officer of Axaron Bioscience AG from November 2001 to August 2002. From October 2001 to January 2002, Dr. Missling served as Head of Financial Planning of Aventis SA, with responsibility for financial modeling and determining investment valuations. From July 1997 to December 1999, he served as Head of Financial Planning at Hoechst AG. Dr. Missling was with Deutsche Bank in corporate finance and investment banking serving pharmaceutical, biotech and diagnostic companies. He served as an Analyst in the pharmaceutical /healthcare investment banking group of Deutsche Morgan Grenfell. Dr. Missling has been Chairman at Anavex Life Sciences Corp. since July 5, 2013. Dr. Missling received his MBA from the Kellogg Graduate School of Management at WHU and Northwestern University, with a focus on partnership valuations in the Biotechnology and Pharmaceutical industries and his Ph.D., in Chemistry, summa cum laude and MSc from Ludwig-Maximilians-University in Munich.

CEO Compensation
  • Chris's compensation has been consistent with company performance over the past year.
  • Chris's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Anavex Life Sciences management team in years:

3.5
Average Tenure
52
Average Age
  • The tenure for the Anavex Life Sciences management team is about average.
Management Team

Chris Missling

TITLE
Chairman
COMPENSATION
$3M
AGE
52
TENURE
5.8 yrs

Sandra Boenisch

TITLE
Principal Financial Officer & Treasurer
COMPENSATION
$232K
AGE
37
TENURE
3.5 yrs

Stephan Toutain

TITLE
Senior Vice President of Operations
AGE
52
TENURE
1.1 yrs

Tayo Fadiran

TITLE
Senior Vice President of Regulatory Affairs

Walter Kaufmann

TITLE
Chief Medical Officer
Board of Directors Tenure

Average tenure and age of the Anavex Life Sciences board of directors in years:

5.4
Average Tenure
48.5
Average Age
  • The tenure for the Anavex Life Sciences board of directors is about average.
Board of Directors

Chris Missling

TITLE
Chairman
COMPENSATION
$3M
AGE
52
TENURE
5.8 yrs

Claus van der Velden

TITLE
Director
COMPENSATION
$120K
AGE
46
TENURE
1.1 yrs

Tangui Maurice

TITLE
Member of the Scientific Advisory Board

Paul Aisen

TITLE
Member of the Scientific Advisory Board
TENURE
8.2 yrs

Jeff Cummings

TITLE
Member of the Scientific Advisory Board
TENURE
8.1 yrs

Tom Skarpelos

TITLE
Director
AGE
51
TENURE
6.3 yrs

Ottavio Arancio

TITLE
Member of the Scientific Advisory Board
TENURE
5.4 yrs

John Harrison

TITLE
Member of the Scientific Advisory Board
TENURE
5.3 yrs

Elliot Favus

TITLE
Director
AGE
43
TENURE
4.9 yrs

Norman Relkin

TITLE
Member of the Scientific Advisory Board
TENURE
4.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Anavex Life Sciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Anavex Life Sciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company’s lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer’s disease; and preclinical clinical trials to treat Parkinson’s disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis. It is also developing ANAVEX 3-71 to treat Alzheimer’s disease; ANAVEX 1-41, a sigma-1 agonist; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was founded in 2006 and is based in New York, New York.

Details
Name: Anavex Life Sciences Corp.
12X1
Exchange: DB
Founded: 2006
$122,014,027
47,480,192
Website: http://www.anavex.com
Address: Anavex Life Sciences Corp.
51 West 52nd Street,
7th Floor,
New York,
New York, 10019,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM AVXL Common Shares Nasdaq Capital Market US USD 13. Apr 2006
DB 12X1 Common Shares Deutsche Boerse AG DE EUR 13. Apr 2006
LSE 0HFR Common Shares London Stock Exchange GB USD 13. Apr 2006
Number of employees
Current staff
Staff numbers
13
Anavex Life Sciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/20 21:53
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/02/08
Last earnings filing: 2019/02/07
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.